WO2012025759A3 - Method - Google Patents

Method Download PDF

Info

Publication number
WO2012025759A3
WO2012025759A3 PCT/GB2011/051608 GB2011051608W WO2012025759A3 WO 2012025759 A3 WO2012025759 A3 WO 2012025759A3 GB 2011051608 W GB2011051608 W GB 2011051608W WO 2012025759 A3 WO2012025759 A3 WO 2012025759A3
Authority
WO
WIPO (PCT)
Prior art keywords
cxcl16
relates
cxcr6
effectiveness
subject
Prior art date
Application number
PCT/GB2011/051608
Other languages
French (fr)
Other versions
WO2012025759A2 (en
Inventor
Peter Beverley
Elma Tchilian
Lian Ni Lee
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1014285.9A external-priority patent/GB201014285D0/en
Priority claimed from GBGB1106785.7A external-priority patent/GB201106785D0/en
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Publication of WO2012025759A2 publication Critical patent/WO2012025759A2/en
Publication of WO2012025759A3 publication Critical patent/WO2012025759A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention relates to methods for determining the effectiveness of pulmonary immunisation of a subject by measuring CXCR6 or CXCL16. The invention also relates to methods for diagnosing a pulmonary infection in a subject or determining the effectiveness of a treatment of a pulmonary infection by measuring CXCR6 or CXCL16. The invention also relates to using CXCL16 as an adjuvant to increase the mononuclear cell response to an antigen.
PCT/GB2011/051608 2010-08-26 2011-08-25 Method WO2012025759A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1014285.9 2010-08-26
GBGB1014285.9A GB201014285D0 (en) 2010-08-26 2010-08-26 Method
GB1106785.7 2011-04-20
GBGB1106785.7A GB201106785D0 (en) 2011-04-20 2011-04-20 Method

Publications (2)

Publication Number Publication Date
WO2012025759A2 WO2012025759A2 (en) 2012-03-01
WO2012025759A3 true WO2012025759A3 (en) 2012-05-10

Family

ID=45723855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/051608 WO2012025759A2 (en) 2010-08-26 2011-08-25 Method

Country Status (1)

Country Link
WO (1) WO2012025759A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110029079B (en) * 2019-03-27 2022-10-11 南京农业大学 Recombinant bacillus subtilis for expressing and secreting porcine pseudorabies virus protein dominant antigen region and application
US20230085475A1 (en) * 2021-08-25 2023-03-16 United Therapeutics Corporation Method to obtain cells from lung tissue
CN115109782B (en) * 2022-05-26 2023-06-09 武汉爱博泰克生物科技有限公司 Expression and renaturation method of recombinant human CXCL16 protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. J. MORGAN ET AL: "Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease", CLINICAL & EXPERIMENTAL ALLERGY, vol. 35, no. 12, 1 December 2005 (2005-12-01), pages 1572 - 1580, XP055013712, ISSN: 0954-7894, DOI: 10.1111/j.1365-2222.2005.02383.x *
J. Q. JIANG ET AL: "Qualitative and Quantitative Characteristics of Rotavirus-Specific CD8 T Cells Vary Depending on the Route of Infection", JOURNAL OF VIROLOGY, vol. 82, no. 14, 15 July 2008 (2008-07-15), pages 6812 - 6819, XP055013756, ISSN: 0022-538X, DOI: 10.1128/JVI.00450-08 *
LIAN NI LEE ET AL: "CXCR6 Is a Marker for Protective Antigen-Specific Cells in the Lungs after Intranasal Immunization against Mycobacterium tuberculosis", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 79, no. 8, 1 August 2011 (2011-08-01), pages 3328 - 3337, XP009154548, ISSN: 0019-9567, DOI: 10.1128/IAI.01133-10 *

Also Published As

Publication number Publication date
WO2012025759A2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
WO2011097301A3 (en) METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
EP2576623A4 (en) Monoclonal antibodies detection methods for enzymes that confer resistance to 2,4-dichlorophenoxyacetic acid in plants
WO2012129341A3 (en) Disease detection in plants
BR112013001752A2 (en) method of detecting disease or condition using phagocytic cells
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
WO2011151252A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2008097866A3 (en) Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
WO2013039477A8 (en) Non-invasive methods of detecting target molecules
WO2008108803A3 (en) Immune cell biosensors and methods of using same
EA201590247A1 (en) ANTIBODIES TO SIGLEC-15
WO2012171949A3 (en) Thromboemoblic disease markers
DK2726883T4 (en) CELL-MEDIATED IMMUNE RESPONSE ASSAY WITH IMPROVED SENSITIVITY
WO2012012704A3 (en) Methods of detecting kidney-associated diseases or conditions
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
IT1401447B1 (en) METHOD FOR THE QUANTITATIVE TRANSFER OF ANALYTES
WO2012012694A3 (en) Methods of detecting autoimmune or immune-related diseases or conditions
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012154983A3 (en) Systems and methods for anti-pax8 antibodies
CY1123265T1 (en) AN ANALYSIS OF CELL-MEDIATED IMMUNE RESPONSE
WO2011156249A3 (en) Yeast concentration and viability measurement
WO2012025759A3 (en) Method
WO2011119986A3 (en) Methods for culturing and analyzing cells
IT1394096B1 (en) METHOD FOR THE DETECTION OF ALLERGENS.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11760530

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11760530

Country of ref document: EP

Kind code of ref document: A2